MiNK Therapeutics, Inc. (INKT)
(Delayed Data from NSDQ)
$0.70 USD
+0.03 (4.17%)
Updated Oct 14, 2024 01:47 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Income Statements
Fiscal Year end for MiNK Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 23 | 31 | 28 | 15 | 23 |
Income After Depreciation & Amortization | -23 | -31 | -28 | -15 | -22 |
Non-Operating Income | 0 | 3 | 1 | 1 | 0 |
Interest Expense | 0 | 0 | 2 | 2 | 2 |
Pretax Income | -22 | -28 | -30 | -16 | -24 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -22 | -28 | -30 | -16 | -24 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -22 | -28 | -30 | -16 | -24 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | -31 | -28 | -15 | -22 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -23 | -31 | -28 | -15 | -22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 34.36 | 33.67 | 26.03 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.65 | -0.83 | -1.16 | NA | NA |
Diluted Net EPS (GAAP) | -0.65 | -0.83 | -1.16 | -0.67 | NA |
Fiscal Year end for MiNK Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.07 | 3.83 | 5.50 | 5.23 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.07 | -3.83 | -5.50 | -5.23 |
Non-Operating Income | NA | 0.37 | 0.02 | 0.36 | 0.11 |
Interest Expense | NA | 0.00 | 0.00 | 0.31 | 0.00 |
Pretax Income | NA | -2.70 | -3.81 | -5.46 | -5.12 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.70 | -3.81 | -5.46 | -5.12 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.70 | -3.81 | -5.46 | -5.12 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 37.14 | 34.64 | 34.56 | 34.50 |
Diluted EPS Before Non-Recurring Items | NA | -0.07 | -0.11 | -0.16 | -0.15 |
Diluted Net EPS (GAAP) | NA | -0.07 | -0.11 | -0.15 | -0.15 |